Is Semaglutide Safe Long Term? What the Research Shows (2026)

One of the most common questions people have before starting semaglutide is: what happens to your body long-term? With millions of people now on GLP-1 medications, we have more data than ever before — including multi-year follow-up studies. Here’s what the evidence actually shows.

The Short Answer

Based on available evidence (up to 4 years of data in some studies), semaglutide appears safe for long-term use in the populations studied. The cardiovascular data is actually favorable — the SELECT trial showed significant reductions in heart attack and stroke risk. The main legitimate long-term concerns involve thyroid tumors (seen in rodent studies, not confirmed in humans), pancreatitis risk, and the need for continued use to maintain weight loss.

Long-Term Safety Data: What Studies Show

Study	Duration	Key Safety Finding
STEP 1 (NEJM 2021)	68 weeks (~16 months)	Well-tolerated; GI side effects peaked early, resolved
STEP 5 (Nature Medicine 2021)	104 weeks (2 years)	Sustained weight loss, continued tolerability; no new safety signals
SELECT (NEJM 2023)	Up to 4+ years	20% reduction in MACE (major cardiovascular events) vs placebo — significant cardiovascular benefit
SUSTAIN-6 (NEJM 2016)	104 weeks	Cardiovascular safety confirmed; reduced heart attack/stroke risk

The Thyroid Cancer Question

Rodent studies found increased rates of thyroid C-cell tumors with GLP-1 receptor agonists, including semaglutide. This led to a boxed warning on Ozempic/Wegovy. However, the human relevance is disputed:

• Rodents have far more GLP-1 receptors in thyroid tissue than humans do
• Post-marketing surveillance across millions of patients has not shown a clear increased rate of medullary thyroid carcinoma (MTC) in humans
• A 2023 study in JAMA Oncology analyzing real-world data found a small increased signal for thyroid cancer — but the study had significant limitations and hasn’t been replicated
• The current FDA recommendation: avoid GLP-1 medications if you have a personal or family history of MTC or MEN2. Otherwise, the risk-benefit calculation generally favors the medications

Cardiovascular Health: A Surprising Upside

The SELECT trial — the largest cardiovascular outcomes trial for semaglutide — enrolled 17,604 adults with overweight/obesity and established cardiovascular disease. Over an average follow-up of ~34 months, the semaglutide group saw a 20% relative reduction in major adverse cardiovascular events (MACE) including heart attack and stroke.

This is remarkable because it was achieved independent of weight loss — even participants who didn’t lose much weight showed cardiovascular benefit. The FDA expanded Wegovy’s label to include cardiovascular risk reduction in 2024 based on this data, making it one of the few obesity medications with a cardiovascular indication.

Pancreatitis Risk

Pancreatitis is listed as a risk for GLP-1 medications. In clinical trials, the rate was low (~0.1–0.2%) and not dramatically higher than placebo. Real-world pharmacovigilance has not shown a clear increased population-level signal, though individual cases do occur.

Who’s at elevated risk: People with a prior history of pancreatitis, gallstones, very high triglycerides, or heavy alcohol use. If you have these risk factors, discuss them with your prescriber before starting.

Kidney Function

Good news here: GLP-1 medications appear to have protective effects on kidney function. The FLOW trial (2024) specifically studied semaglutide in people with type 2 diabetes and chronic kidney disease — it showed a 24% reduction in kidney failure, doubling of creatinine, and cardiovascular death. FDA approved a kidney protection indication for Ozempic in 2024.

Mental Health Considerations

Post-marketing reports have raised questions about suicidal ideation and depression in people taking GLP-1 medications. The FDA conducted a review and concluded there was no clear causal link — but monitoring continues. The mechanism that suppresses appetite via the reward pathway might theoretically affect mood in some people.

Anecdotally, many users report improved mental health associated with weight loss and better metabolic health. The relationship is complex. If you notice significant mood changes on GLP-1 therapy, discuss them with your provider.

The Muscle Loss Concern

Long-term use raises valid questions about muscle mass preservation. Studies show 25–40% of weight lost on semaglutide can be lean mass. Over multiple years on the medication, without deliberate resistance training, this could meaningfully reduce muscle mass and metabolic rate.

Mitigation: Resistance training 2–3x per week and protein intake of 0.7–1g per pound of goal body weight effectively reduces muscle loss during GLP-1 therapy. This should be considered part of the treatment program, not optional.

Bottom Line: Is Long-Term Use Safe?

For most people in the populations that have been studied, the evidence supports long-term safety with meaningful benefits. The cardiovascular and kidney protection data is particularly compelling. The main uncertainties (thyroid cancer in humans, very long-term effects beyond 4 years) remain open questions that ongoing surveillance will answer.

As with any long-term medication, the benefit-risk calculation depends on individual factors — your cardiovascular risk profile, weight-related comorbidities, and alternative options. That’s a conversation to have with a qualified prescriber.